Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AMBUJACEM.NS Stock Summary
In the News
AMBUJACEM.NS Financial details
Company Rating
Strong Buy
Market Cap
1170.24B
Income
23.95B
Revenue
312.46B
Book val./share
165.58
Cash/share
65.27
Dividend
2.5
Dividend %
0.47%
Employees
4.36K
Optionable
No
Shortable
Yes
Earnings
25 Jun 2024
P/E
43.7
Forward P/E
38.76
PEG
-12.01
P/S
3.35
P/B
3.18
P/C
9.38
P/FCF
-
Quick Ratio
1.32
Current Ratio
1.82
Debt / Equity
0.02
LT Debt / Equity
0.01
-
-
EPS (TTM)
11.89
EPS next Y
15.8
EPS next Q
4.04
EPS this Y
-49.97%
EPS next Y
32.92%
EPS next 5Y
60.83%
EPS last 5Y
-8.98%
Revenue last 5Y
4.07%
Revenue Q/Q
-14.79%
EPS Q/Q
-12.5%
-
-
-
-
SMA20
-0.69%
SMA50
11.99%
SMA100
41.39%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
29%
ROC
0.09%
Gross Margin
80%
Oper. Margin
13%
Profit Margin
8%
Payout
-
Shs Outstand
1.99B
Shs Float
727.99M
-
-
-
-
Target Price
-
52W Range
354.3-625.0
52W High
-2.02%
52W Low
+72.98%
RSI
59.61
Rel Volume
0.99
Avg Volume
3.91M
Volume
3.86M
Perf Week
4.74%
Perf Month
7.26%
Perf Quarter
40.54%
Perf Half Y
42.49%
-
-
-
-
Beta
0.116
-
-
Volatility
11.5%, 14.02%
Prev Close
1.8%
Price
612.35
Change
2.4%
AMBUJACEM.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 128.01 | 133.65 | 121.34 | 143.77 | 150.77 | |
Net income per share | 14.97 | 10.55 | 11.91 | 18.69 | 9.35 | |
Operating cash flow per share | 8.7 | 23.86 | 24.34 | 26.74 | 2.86 | |
Free cash flow per share | 3.12 | 15.47 | 15.61 | 14.98 | -13.59 | |
Cash per share | 32.43 | 46.91 | 43.41 | 57.38 | 47.37 | |
Book value per share | 112.66 | 121.26 | 114.61 | 127.69 | 68.34 | |
Tangible book value per share | 98.62 | 109.38 | 105.77 | 122.91 | 148.27 | |
Share holders equity per share | 112.66 | 121.26 | 114.61 | 127.69 | 68.34 | |
Interest debt per share | 1.03 | 1.04 | 3.05 | 3.1 | 0.17 | |
Market cap | 446.97B | 389.68B | 494.13B | 749.58B | 752.52B | |
Enterprise value | 386.43B | 299.97B | 413.12B | 640.76B | 747.08B | |
P/E ratio | 15.04 | 18.6 | 20.89 | 20.2 | 39.1 | |
Price to sales ratio | 1.76 | 1.47 | 2.05 | 2.63 | 2.42 | |
POCF ratio | 25.89 | 8.22 | 10.23 | 14.12 | 127.99 | |
PFCF ratio | 72.25 | 12.69 | 15.95 | 25.2 | -26.9 | |
P/B Ratio | 2 | 1.62 | 2.17 | 2.96 | 5.35 | |
PTB ratio | 2 | 1.62 | 2.17 | 2.96 | 5.35 | |
EV to sales | 1.52 | 1.13 | 1.71 | 2.24 | 2.41 | |
Enterprise value over EBITDA | 8.96 | 5.81 | 7.57 | 9.79 | 20.62 | |
EV to operating cash flow | 22.38 | 6.33 | 8.55 | 12.07 | 127.07 | |
EV to free cash flow | 62.47 | 9.77 | 13.33 | 21.54 | -26.71 | |
Earnings yield | 0.07 | 0.05 | 0.05 | 0.05 | 0.03 | |
Free cash flow yield | 0.01 | 0.08 | 0.06 | 0.04 | -0.04 | |
Debt to equity | 0 | 0 | 0.02 | 0.02 | 0 | |
Debt to assets | 0 | 0 | 0.01 | 0.01 | 0 | |
Net debt to EBITDA | -1.4 | -1.74 | -1.48 | -1.66 | -0.15 | |
Current ratio | 1.48 | 1.58 | 1.38 | 1.52 | 1.67 | |
Interest coverage | 19.19 | 24.22 | 32.04 | 38.91 | 0 | |
Income quality | 0.59 | 1.22 | 1.21 | 1.03 | 0.31 | |
Dividend Yield | 0.01 | 0.01 | 0.07 | 0 | 0.01 | |
Payout ratio | 0.18 | 0.14 | 1.55 | 0.05 | 0.52 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0.06 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0.01 | |
Intangibles to total assets | 0.21 | 0.2 | 0.2 | 0.18 | 0.16 | |
Capex to operating cash flow | -0.64 | -0.35 | -0.36 | -0.44 | -5.76 | |
Capex to revenue | -0.04 | -0.06 | -0.07 | -0.08 | -0.11 | |
Capex to depreciation | -0.96 | -1.45 | -1.49 | -2.03 | -2.58 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 194.81 | 169.66 | 175.27 | 231.72 | 119.9 | |
ROIC | 0.14 | 0.12 | 0.14 | 0.15 | 0.14 | |
Return on tangible assets | 0.1 | 0.07 | 0.07 | 0.1 | 0.04 | |
Graham Net | 2.01 | 10.78 | 3.5 | 11.1 | -7.66 | |
Working capital | 40.27B | 52.49B | 35.44B | 57.95B | 77.36B | |
Tangible asset value | 195.82B | 217.19B | 210.02B | 244.05B | 305.23B | |
Net current asset value | 26.82B | 39.51B | 21.83B | 43.14B | 62.84B | |
Invested capital | 0 | 0 | 0.02 | 0.02 | 0 | |
Average receivables | 26.42B | 29.1B | 26.8B | 26.84B | 14.34B | |
Average payables | 29.02B | 26.7B | 22.73B | 25.63B | 28.43B | |
Average inventory | 27.08B | 25.27B | 18.73B | 21.93B | 30.05B | |
Days sales outstanding | 42.5 | 39.33 | 37.87 | 36.66 | 0 | |
Days payables outstanding | 213.51 | 153.62 | 176.15 | 216.12 | 70.99 | |
Days of inventory on hand | 210.08 | 138.05 | 131.2 | 203.15 | 83.76 | |
Receivables turnover | 8.59 | 9.28 | 9.64 | 9.96 | 0 | |
Payables turnover | 1.71 | 2.38 | 2.07 | 1.69 | 5.14 | |
Inventory turnover | 1.74 | 2.64 | 2.78 | 1.8 | 4.36 | |
ROE | 0.13 | 0.09 | 0.1 | 0.15 | 0.14 | |
Capex per share | -5.58 | -8.4 | -8.73 | -11.75 | -16.45 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-06-30 | 2022-09-30 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 40.48 | 36.03 | 38.04 | 43.87 | 37.36 | |
Net income per share | 3.79 | 0.26 | 3.08 | 4.56 | 3.99 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 45.09 | 0 | 14.14 | 0 | 65.27 | |
Book value per share | 128.66 | 0 | 1.9 | 0 | 165.58 | |
Tangible book value per share | 122.77 | 0 | 145.76 | 0 | 161.31 | |
Share holders equity per share | 128.66 | 0 | 1.9 | 0 | 165.58 | |
Interest debt per share | 2.59 | 0.2 | -0.02 | 0.26 | 4.06 | |
Market cap | 720.25B | 1022.2B | 765.45B | 845.83B | 844.23B | |
Enterprise value | 643.45B | 1022.2B | 735.84B | 845.83B | 840.32B | |
P/E ratio | 23.94 | 498.15 | 29.67 | 23.35 | 26.62 | |
Price to sales ratio | 8.97 | 14.31 | 9.61 | 9.71 | 11.37 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 2.82 | 0 | 192.74 | 0 | 2.57 | |
PTB ratio | 2.82 | 0 | 192.74 | 0 | 2.57 | |
EV to sales | 8.01 | 14.31 | 9.24 | 9.71 | 11.32 | |
Enterprise value over EBITDA | 51.3 | 231.68 | 60.53 | 43.7 | 47.16 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.02 | 0 | 0.09 | 0 | 0.02 | |
Debt to assets | 0.01 | 0 | 0 | 0 | 0.01 | |
Net debt to EBITDA | -6.12 | 0 | -2.44 | 0 | -0.22 | |
Current ratio | 1.43 | 0 | 1.67 | 0 | 1.82 | |
Interest coverage | 23.41 | 2.73 | -22.49 | 30.03 | 22.87 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.05 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.18 | 0 | 0.16 | 0 | 0.15 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 104.74 | 0 | 11.46 | 0 | 121.92 | |
ROIC | 0.03 | 0 | 1.59 | 0 | 0.03 | |
Return on tangible assets | 0.02 | 0 | 0.01 | 0 | 0.02 | |
Graham Net | -3.07 | 0 | -39.96 | 0 | 16.71 | |
Working capital | 47.9B | 85.04B | 77.36B | 97.51B | 94.41B | |
Tangible asset value | 243.59B | 0 | 305.23B | 0 | 320.57B | |
Net current asset value | 33.8B | 85.04B | 62.84B | 97.51B | 78.43B | |
Invested capital | 0.02 | 0 | 0.09 | 0 | 0.02 | |
Average receivables | 7.68B | 7.68B | 0 | 0 | 10.83B | |
Average payables | 14.85B | 14.85B | 0 | 13.87B | 12.35B | |
Average inventory | 18.72B | 18.72B | 0 | 16.36B | 18B | |
Days sales outstanding | 17.21 | 0 | 0 | 0 | 26.27 | |
Days payables outstanding | 355.62 | 0 | 73.72 | 0 | 215.27 | |
Days of inventory on hand | 448.44 | 0 | 86.98 | 0 | 313.65 | |
Receivables turnover | 5.23 | 0 | 0 | 0 | 3.43 | |
Payables turnover | 0.25 | 0 | 1.22 | 0 | 0.42 | |
Inventory turnover | 0.2 | 0 | 1.03 | 0 | 0.29 | |
ROE | 0.03 | 0 | 1.62 | 0 | 0.02 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AMBUJACEM.NS Frequently Asked Questions
What is Ambuja Cements Limited stock symbol ?
Ambuja Cements Limited is a IN stock and trading under the symbol AMBUJACEM.NS
What is Ambuja Cements Limited stock quote today ?
Ambuja Cements Limited stock price is $612.35 today.
Is Ambuja Cements Limited stock public?
Yes, Ambuja Cements Limited is a publicly traded company.